Scribd Logo
Загрузить

Добро пожаловать в Scribd!

  • Texto

    Загружено:

    Denditric Cell
    6 просмотров2 страницы
    Word -

    Оригинальное название

    • Texto Copia

    Авторское право

    © © All Rights Reserved

    Доступные форматы

    DOCX, PDF, TXT или читайте онлайн в Scribd

    Этот документ был вам полезен?

    Это неприемлемый материал?

    Пожаловаться на этот документ
    Word -

    Авторское право:

    © All Rights Reserved
    Скачайте в формате DOCX, PDF, TXT или читайте онлайн в Scribd
    Отметить как неприемлемый контент
    6 просмотров2 страницы

    Texto

    Загружено:

    Denditric Cell
    Word -

    Авторское право:

    © All Rights Reserved
    Скачайте в формате DOCX, PDF, TXT или читайте онлайн в Scribd
    Отметить как неприемлемый контент
    из 2

    >1,000 patients who presented with

    possible
    ACS before and after the introduction
    of a
    lower di
    nted with possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocard
    ction of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variabili
    al infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)

    using a high-sensitivity troponin


    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    1

    lower diagnostic threshold (from 0.20


    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1

    >1,000 patients who presented with


    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a

    lower diagnostic threshold (from 0.20


    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)

    using a high-sensitivity troponin


    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The
    >1,000 patients who presented with
    possible
    ACS before and after the introduction
    of a
    lower diagnostic threshold (from 0.20
    ng/ml
    to 0.05 ng/ml) for myocardial
    infarction (MI)
    using a high-sensitivity troponin
    assay with
    a low coefficient of variability
    (<10%).1 The

    Вам также может понравиться